Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.

Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].

Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.